View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 22, 2021

Perception’s PCN-101 safe and well-tolerated in Phase I clinical study

Perception Neuroscience has reported positive data from its first Phase 1 clinical study of PCN-101 (R-ketamine) in healthy adult participants.

Perception Neuroscience has reported positive data from its first Phase 1 clinical study of PCN-101 (R-ketamine) in healthy adult participants.

A stereoisomer of ketamine, R-ketamine is being developed for treating psychiatric illnesses such as treatment-resistant depression (TRD).

The single-centre, randomised, placebo-controlled, double-blind single ascending dose study analysed the safety, tolerability and pharmacokinetics of PCN-101. It also included a subsequent relative safety comparison of PCN-101 and S-ketamine.

In the study, healthy participants received a single 40-minute intravenous infusion of PCN-101 or a placebo.

The initial stage of the two-stage study analysed the safety, tolerability and pharmacokinetics of single ascending doses of PCN-101 in 58 healthy adult participants versus placebo.

Results showed that PCN-101 was safe and well-tolerated at all doses up to the highest dose tested of 150mg.

PCN-101’s pharmacokinetics in plasma was about dose-proportional with no serious adverse events reported in the study.

The study’s second stage analysed the relative safety and tolerability of PCN-101 to that of S-ketamine. Data showed that PCN-101 needed higher doses to stimulate similar perceptual changes than S-ketamine.

Perception Neuroscience CEO Terence Kelly said: “We are excited by the Phase I results that support the hypothesis that PCN-101 can be developed as a rapidly acting antidepressant with the potential for at-home use.

“The upcoming Phase II proof-of-concept trial in patients with Treatment Resistant Depression is the next important step in demonstrating the full potential of PCN-101.”

The company has obtained additional funding in a financing round that was led by atai Life Sciences to initiate the Phase IIa proof-of-concept study of PCN-101. This study is anticipated to begin in the second quarter of this year.

atai Life Sciences CEO and co-founder Florian Brand said: “The success of Perception’s Phase I clinical study leads us to believe that PCN-101 has the potential to offer a highly differentiated profile from current treatment options.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU